Business Context and Reporting Period
This Form 8-K Current Report was filed by Dianthus Therapeutics, Inc. on March 5, 2025, covering events that occurred on March 4, 2025. The filing addresses changes to the Company's Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
- Resignation: Tomas Kiselak resigned from the Board of Directors effective March 4, 2025. The resignation was not due to any disagreement with the Company regarding operations, policies, or practices.
- Appointment: Sujay Kango was appointed as a Class II director and a member of the Compensation Committee, effective immediately following the close of business on March 4, 2025.
Compensation and Governance Details
Mr. Kango's appointment includes the following compensatory arrangements under the Company's Non-Employee Director Compensation Policy:
- Equity Grant: An initial option to purchase 25,000 shares of common stock, vesting in three equal tranches over three years, contingent on continued service.
- Cash Compensation: $40,000 per year for Board service and $6,000 per year for Compensation Committee service, payable quarterly and prorated for partial service periods.
- Future Awards: Eligibility for annual equity grants in accordance with the Policy.
- Indemnification: Mr. Kango will enter into a standard indemnification agreement.
Investor Verification Checklist
- Verify the effective date of Tomas Kiselak's resignation and confirm no undisclosed disagreements exist.
- Confirm Sujay Kango's qualifications and background as a new Class II director.
- Review the specific vesting schedule and exercise terms of the 25,000-share option grant.
- Check the Company's current cash position to ensure it can meet the new annual cash compensation obligations of $46,000.